Oxford Cannabinoid Technologies Holdings plc was incorporated as a public limited company on 4 February 2021 with registration number 13179529. OCT is a UK-based pharmaceutical company specialised in cannabinoid drug development. The Company’s vision is to become a global leader in developing licensed prescription medicines that target the endocannabinoid system and address significant unmet medical needs. The Group’s primary market focus is the total addressable pain market, which is estimated to be worth at least £42.5 billion(1) by commercialisation of the first drug produced by OCT, currently anticipated to be in 2027, and as such it initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.